A study of NCAA Division I football players revealed persistent atrophy in the quadriceps and gastrocnemius muscles 2 years ...
Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...
More research is needed to confirm gray matter, the darker tissue found in the brain and spinal cord, “as a potential disease ...
MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...
If your foot hurts when walking, it could be caused by overuse, injury, or multiple medical conditions. Here are the common ...
Biogen said the U.S. Food and Drug Administration has accepted its supplemental new-drug application, while the European Medicines Agency has validated its application, which confirms that the ...
We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...
The following is a summary of “Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback